Format

Send to

Choose Destination
Biol Blood Marrow Transplant. 2017 Mar;23(3):529-532. doi: 10.1016/j.bbmt.2016.12.627. Epub 2016 Dec 21.

Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling.

Author information

1
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
2
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana.
3
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: brian.engelhardt@vanderbilt.edu.

Abstract

New-onset post-transplantation diabetes mellitus (PTDM) occurs commonly after allogeneic hematopoietic cell transplantation (HCT) and is associated with inferior survival. We hypothesize that PTDM and nonrelapse mortality (NRM) are related to IL-33/suppression of tumorigenicity 2 (ST2) signaling and that soluble ST2 (sST2) levels will predict PTDM diagnosis. sST2 was measured at engraftment and day +30 in 36 euglycemic HCT recipients followed prospectively for PTDM (cohort 1). Results were confirmed in a validation cohort of 26 patients without pre-existing diabetes analyzed retrospectively for PTDM (cohort 2). Twelve patients with established diabetes before HCT were analyzed in cohort 3. When compared with recipients without PTDM, patients developing PTDM (n = 24) from cohort 1 had elevated sST2 levels at engraftment (P = .02) and at day +30 (P < .01). Cohort 2 confirmed this finding at engraftment (P = .01). Cohort 3 patients with pretransplantation diabetes had higher sST2 at engraftment than patients maintaining euglycemia after HCT from cohort 2 (P = .03). Multivariate analysis of cohorts 1 and 2 showed high engraftment sST2 predicted increased PTDM and NRM risk, independent of conditioning and grades 3 to 4 acute graft-versus-host-disease. sST2 was elevated in PTDM, indicating a relationship between glucose homeostasis and the IL-33/ST2 axis after transplantation. Correction of metabolic complications may decrease sST2 and improve NRM.

KEYWORDS:

Allogeneic; IL-33; Metabolic complications; Post-transplantation diabetes mellitus; Soluble suppression of tumorigenicity 2; Treatment-related mortality; sST2

PMID:
28013014
PMCID:
PMC5321545
DOI:
10.1016/j.bbmt.2016.12.627
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center